Strange G - Search Results

1

Valvuloarterial Impedance and 5-Year Mortality in Severe Aortic Stenosis.

Lan NSR, Ihdayhid AR, Boardman G, Strange G, Playford D, Dwivedi G. Lan NSR, et al. Among authors: strange g. Anatol J Cardiol. 2023 Mar;27(3):132-134. doi: 10.14744/AnatolJCardiol.2022.2498. Anatol J Cardiol. 2023. PMID: 36856590 Free PMC article. No abstract available.

2

EXPRESS: PHSANZ ASM 2017 - Abstracts.

Strange GA. Strange GA. Pulm Circ. 2018 Jan 1;8(2):2045894018759919. doi: 10.1177/2045894018759919. Online ahead of print. Pulm Circ. 2018. PMID: 29480153 Free PMC article. No abstract available.

3

Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.

Strange G, Keogh AM, Williams TJ, Wlodarczyk J, McNeil KD, Gabbay E. Strange G, et al. Respirology. 2008 Sep;13(5):674-82. doi: 10.1111/j.1440-1843.2008.01326.x. Respirology. 2008. PMID: 18713089

4

Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension.

Strange G, Keogh A, Dalton B, Gabbay E. Strange G, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Jun;11(3):253-63. doi: 10.1586/erp.11.26. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21671693 Review.

5

Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study.

Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, Keogh A. Strange G, et al. Pulm Circ. 2013 Jan;3(1):89-94. doi: 10.4103/2045-8932.109919. Pulm Circ. 2013. PMID: 23662179 Free PMC article.

6

Risk stratification in pulmonary arterial hypertension using Bayesian analysis.

Kanwar MK, Gomberg-Maitland M, Hoeper M, Pausch C, Pittrow D, Strange G, Anderson JJ, Zhao C, Scott JV, Druzdzel MJ, Kraisangka J, Lohmueller L, Antaki J, Benza RL. Kanwar MK, et al. Among authors: strange g. Eur Respir J. 2020 Aug 27;56(2):2000008. doi: 10.1183/13993003.00008-2020. Print 2020 Aug. Eur Respir J. 2020. PMID: 32366491 Free PMC article.

7

Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.

Keogh A, Strange G, Kotlyar E, Williams T, Kilpatrick D, Macdonald P, Brown K, Pidoux A, Kermeen F, Steele P, Dalton B, Gabbay E. Keogh A, et al. Among authors: strange g. Intern Med J. 2011 Mar;41(3):235-44. doi: 10.1111/j.1445-5994.2010.02403.x. Intern Med J. 2011. PMID: 21118410

8

The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy.

Strange G, Nash P. Strange G, et al. Int J Rheum Dis. 2009 Sep;12(3):192-206. doi: 10.1111/j.1756-185X.2009.01410.x. Int J Rheum Dis. 2009. PMID: 20374346 Review.

9

Integrated care and optimal management of pulmonary arterial hypertension.

Strange G, Fowler R, Jary C, Dalton B, Stewart S, Gabbay E. Strange G, et al. J Multidiscip Healthc. 2009 May 12;2:67-78. doi: 10.2147/jmdh.s3085. J Multidiscip Healthc. 2009. PMID: 21197349 Free PMC article.

10

The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.

Keogh A, Strange G, McNeil K, Williams TJ, Gabbay E, Proudman S, Weintraub RG, Wlodarczyk J, Dalton B. Keogh A, et al. Among authors: strange g. Intern Med J. 2011 Mar;41(3):227-34. doi: 10.1111/j.1445-5994.2009.02139.x. Intern Med J. 2011. PMID: 20002851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters